Researchers Suggest Mining Mouse Studies for Better Aging-Rate Markers
The absence of a reliable biological age measure slows progress in testing interventions that might slow aging. A new paper proposes using data from mouse Interventions Testing Program studies to identify shared biochemical and metabolic markers of slowed aging. This approach may work for therapies that act through stress-response and maintenance pathways, though its relevance to senolytics or stem cell therapies remains uncertain.
A reliable way to gauge biological age remains elusive, slowing efforts to test treatments that might delay aging. Without such a measure, researchers cannot easily tell whether a new approach truly works, and mouse lifespan experiments can take years.
The paper points to the National Institute on Aging's Interventions Testing Program, where 14 agents or combinations have extended mouse lifespan, often begun in late adulthood. It proposes 12 candidate aging-rate indicators based on shared molecular and physiological changes. These may fit stress-response and maintenance therapies, but their value for senolytics or stem cell treatments is unclear.
If validated, these proxy markers could speed selection of anti-aging interventions, potentially benefiting older adults and researchers by reducing reliance on lengthy mouse lifespan studies. Drug developers and clinicians may gain earlier signals about whether therapies affect aging biology. Yet uncertainty for senolytics and stem cell approaches means impact may be uneven. Patients might eventually see faster testing of preventive treatments, but only if markers prove robust across diverse interventions.